verti-cally transmitted humanimmunodeficiency virus-1
16. Cunningham-Rundles, S., Ahrn, S., Abuav-Nussbaum, R. & infection: The prospective, P2C2 human immunodeficiency
Dnistrian, A. Development of immunocompetence: role of virus multicenter study. Pediatrics 108 (2001), 1287–96.
micronutrients andmicroorganisms. Nutr. Rev. 60(2002), S68–
33. Hilgartner, M. W., Donfield, S. M., Lynn, H. S. et al. The effect
of plasma human immunodeficiency virus RNA and CD4 +T
17. Chantry, C. J., Byrd, R. S., Englund, J. A. et al.Growth, lymphocytes on growth measurements of hemophilic boys
survival and viral load in symptomatic childhood human and adolescents. Pediatrics 107 (2001), e56.
immunod-eficiency virus infection. Pediatr. Infect. Dis. J.
34. Nachman, S. A., Lindsey, J. C., Pelton, S. et al.Growth
22(12) (2003), 1033–9.
in human immunodeficiency virus-infected children receiving
18. McKinney, R. E. Jr. & Wilfert, C. Growth as a prognostic ritonavircontaining antiretroviral therapy. Arch. Pediatr.
indicator in children with human immunodeficiency virus Adolesc. Med. 156 (2002), 497–503.
infection treated with zidovudine. AIDS Clinical Trials Group
35. Buchacz, K., Cervia, J. S., Lindsey, J. C. et al. for the Pediatric
Protocol 043 Study Group. J. Pediatr. 125 (1994), 728–33.
AIDS Clinical Trials Group 219 Study Team. Impact of
19. Berhane, R., Bagenda, D., Marum, L. et al.Growth failure as a protease inhibitor-containing combination antiretroviral
prognostic indicator of mortality in pediatric HIV infection. therapies on height and weight growth in HIV-infected
Pediatrics 100 (1997), e7. children. Pediatrics 108 (2001), e72.
20. Yong,F. H., Stanley, K., McKinney, R. E., 36. Verweel, G., van Rossum, A. M. C., Hartwig, N. G., Wolfs, T.
et al.Prognosticvalue of plasmaRNA,CD4,andgrowthmarkers F., Scherpbier, H. J. & de Groot, R. Treatment with highly
for clinical disease pro-gression in children with HIV disease. active antiretroviral therapy in human immunodeficiency
Intersci. Conf. Antimi-crob. Agents Chemother. (ICAAC) 38 virustype-1-infected children is associated with a sustained
(Sept 24–27, 1998), 364 [Abstract no. I-7]. effect on growth. Pediatrics 109 (2002), e25.
21. Campa,A., Shor-Posner G, Indacochea, F. et al.Mortality risk in 37. Abrams, B., Duncan, D. & Hertz-Picciotto, H. A prospect-ive
selenium-deficient HIV-positive children. J. Acquir. Immune. study of dietary intake and acquired immune deficiency
Defic. Syndr. Hum. Retrovirol. 20 (1999), 508–13. syndrome in HIV-seropositive homosexual men. J. Acquir.
22. Duggan, C. & Fawzi, W. Micronutrients and child health: stud- Immune. Defic. Syndr. 6 (1993), 949–58.
ies in international nutrition and HIV infection. Nutr. Rev. 59 38. Dunn, A. M., Cervia, J., Burgess, A. et al.Failure to thrive in
(2001), 358–69. the HIV-infected child. 11 th Int Conf AIDS 1 (1996), 319
23. Rodr?yguez, J. F., Cordero, J., Chantry, C. J. et al.Glutathione [Abstract 2312]. 39. Heller, L. S. Nutritional support for
levels in HIV-infected children. Pediatr. Infect. Dis. J. 17 children with HIV/AIDS. AIDS Reader 10 (2000), 109–14.
(1998), 236–41. 40. Allard, J. P., Aghdassi, E., Chau, J., Salit, I. &Walmsley, S.
24. Omene, J. A., Easington, C. R., Glew, R. H., Prosper, M. Oxida-tive stress and plasma antioxidant micronutrients in
&Ledlie, S. Serum beta-carotene deficiency in HIV-infected humans with HIV infection. Am.J.Clin. Nutr. 67 (1998), 1443–
children. J. Natl. Med. Assoc. 88 (1996), 789–93. 7.
25. Fawzi, W. W., Mbise, R. L., Hertzmark, E. et al.Arandomized 41. Mintz, M. Carnitine in human immunodeficiency virus type
trial of vitamin A supplements in relation to mortality among 1 infection/acquired immune deficiency syndrome. J. Child.
humanimmunodeficiencyvirus-infected anduninfectedchil-dren Neurol. 10 (1995), 2S40–44.
in Tanzania. Pediatr. Infect. Dis. J. 18 (1999), 127–33. 42. Haug, C. J., Aukrust, P., Haug, E., Morkrid, L., Muller, F.
26. Moye, J. Jr., Rich, K. C., Kalish, L. A. et al.Natural history of &Froland, S. S. Severe deficiency of 1,25-dihyroxyvitamin
somatic growth in infants born to women infected by human D3 in human immunodeficiency virus infection: association
immunodeficiency virus. Women and Infants Transmission with immunological hyperactivity and only minor changes in
Study Group. J. Pediatr. 128 (1996), 58–69. calcium homeostasis. J. Clin. Endocrinol. Metab. 83 (1998),
27. Miller, T. L., Evans, S., Orav, E. J., Morris, V., McIntosh, K. &
Winter, H. S. Growth and body composition in children with 43. Henderson, R. A., Talusan, K., Hutton, N., Yolken, R. H. &
human immunodeficiency virus-1 infection. Am.J.Clin. Nutr. Caballero, B. Serum and plasma markers of nutritional sta-tus
57 (1993), 588–92. in children infected with the human immunodeficiency
virus. J. Am. Diet. Assoc. 97 (1997), 1377–81.
28. Fontana, M., Zuin, G., Plebani, A. et al.Body composition in
HIV-infected children: relations with disease progression and 44. Skurnick, J. H., Bogden, J. D., Baker, H. et al.Micronutrient
survival. Am.J.Clin. Nutr. 69 (1999), 1282–6. pro-files in HIV-1-infected heterosexual adults. J. AIDS 12
29. Arpadi, S. M., Cuff, P. A., Kotler, D. P. et al.Growth velocity,
fat-free mass and energy intake are inversely related to viral 45. Horlick, M., Arpadi, S. M., Bethel, J. et al.Bioelectrical
load in HIV-infected children. J. Nutr. 130 (2000), 2498–502. impedance analysis models for prediction of total body water
and fat-free mass in healthy and HIV-infected children and
30. Moye, J., Frederick, M., Chantry, C. et al. for the Women
adolescents. Am.J.Clin. Nutr. 76 (2002), 991–9.
and Infants Transmission Study. 10-year follow-up of somatic
growth in children bornto womeninfected by humanimmun-
Руководство по оказанию помощи ВИЧ-инфицированным детям. Под ред. С. Зайхнера и Дж. Рид
Питание, рост и метаболизм
46. Freedman, D. S., Serdula, M. K., Srnivasan, S. R. & Beren-son, 62. Miller, T. L., Awnetwant, E. L., Evans, S., Morris, V. M.,
G. S. Relation of circumferences and skinfold thicknesses Vazquez, I. M. & McIntosh, K. Gastrostomy tube
to lipid and insulin concentrations in children and adoles-cents: supplementation for HIV infected children. Pediatrics 96
the Bogalusa Heart Study. Am.J.Clin. Nutr. 69 (1999), (1995), 696–702.
308–17. 63. Sinden, A. A., Dillard, V. L. & Sutphen, J. L. Enteral nutrition.
47. Taylor, R. W., Jones, I. E., Williams, S. M. &Goulding, A. In W. A., Walker, P. R., Durie, J. R., Hamilton, J. A., Walker-
Evaluation of waist circumference, waist-to-hip ratio, and the Smith & J. B. Watkins (eds.), Pediatric Gastrointestinal
conicity index as screening tools for high trunk fat mass, as Disease. Philadelphia, PA: BC Decker, Inc. (1991), p. 1636.
mea-sured by dual-energy X-ray absorptiometry, in children 64. Miller, T. L., Orav, E. J., Martin, S. R. et al.Malnutrition
aged 3–19 years. Am.J.Clin. Nutr. 72 (2000), 490–5. and carbohydrate malabsorption in children with vertically-
48. Goran, M. I., Gower, B. A., Treuth, M. & Nagy, T. R. transmitted human immunodeficiency virus-1 infection.
Prediction of intraabdominal and subcutaneous abdominal Gastroenterology 100 (1991), 1296–302.
adipose tissue in healthy pre-pubertal children. Int. J. Obes. 65. The Italian Pediatric Intestinal/HIV Study Group. Intestinal
Relat. Metab. malabsorption of HIV-infected children: relationship to diar-
Disord. 22 (1998), 549–68. rhea, failure to thrive, enteric micro-organisms and immune
49. Johann-Liang, R., O’Neill, L., Cervia, J. et al.Energy balance, impairment. AIDS 7 (1993), 1435–40.
viral burden, insulin-like growth factor-1, interleukin-6 and 66. Mulligan, K., Tai, V. W. &Schambelan,M.Energyexpenditurein
growthimpairmentin childreninfected with humanimmuno- human immunodeficiency virus infection [letter]. New Engl.
deficiency virus. AIDS 14 (2000), 683–90. J. Med. 70 (1997), 70–1.
50. Guo, S., Roche, A. F., Foman, S. J. et al.Reference data on 67. Chiarelli, F., Galli, L., Verrotti, A., diRocco, L., Vierucci, A. &
gains in weight and length during the first two years of life. J. de Martino, M. Thyroid function in children with perinatal
Pediatr. 119 (1991), 355–62. human immunodeficiency virus type 1 infection. Thyroid 10
51. Karlberg, P., Taranger, J., Engstrom, I. et al.I.Physical growth (2000), 499–505.
from birth to 16 years and longitudinal outcome of the study 68. Laue, L., Pizzo, P. A., Butler, K. & Cutler, G. B., Jr. Growth
during the same age period. Acta. Pediatr. Scand. Suppl. 258 and neuroendocrine dysfunction in children with acquired
(1976), 7–76. immunodeficiency syndrome. J. Pediatr. 117 (1990), 541–5.
52. Sentongo, T. A., Rutstein, R. M., Stettler, N. et al. Association 69. Jospe, N. & Powell, K. R. Growth hormone deficiency in an 8-
between steatorrhea, growth, and immunologic status in chil- year old girl with human immunodeficiency virus infection.
dren with perinatally acquired HIV infection. Arch. Pediatr. Pediatrics 86 (1990), 309–12.
Adolesc. Med. 155 (2001), 149–53.
70. Cieslak, T. J., Ascher,D. P., Zimmerman,P. A. et
53. Alfaro, M. P., Siegel, R. M., Baker, R. C. & Heubi, J. E. al.Adrenalinsuf-ficiency presenting as HIV wasting syndrome
Resting energy expenditure and body composition in pediatric in a child: initial successful response to megestrol. Pediatr.
HIV infection. Pediatr. AIDS HIV Infect. 6 (1995), 276–80. AIDS HIV Infect. 2 (1991), 279–83.
54. Henderson, R. A., Talusan, K., Hutton, N., Yolken, R. H. & 71. Frost, R. A., Nachman, S. A., Lang, C. H. & Gelato, M. C.
Caballero, B. Resting energy expenditure and body compo- Proteolysis of insulin-like growth factor-binding protein-3 in
sition in children with HIV infection. J. AIDS Hum. Retrovirol. human immunodeficiency virus-positive children with fail-ure
19 (1998), 150–7. to thrive. J. Clin. Endocrinol. Metab. 81 (1996), 2957–
55. Clarick, R. H., Hanekom, W. A., Yogev, R. & Chadwick, E. G. 62.
Megestrol acetate treatment of growth failure in children 72. Guyda, H. J. Howdo we best measure growth hormone action?
infected with human immunodeficiency virus. Pediatrics, Horm. Res. 48 (Suppl. 5) (1997), 1–10.
99(3) (1997), 354–7.
73. Gelato, M. C. & Frost, R. A. IGFBP-3. Functional and
56. Mann, M., Koller, E., Murgo, A., Malozowski, S., Bacsanyi, structural implications in aging and wasting syndromes.
J. & Leinung, M. Glucocorticoid like activity of megestrol: a Endocrine 7:1 (1997), 81–5.
summary of Food and Drug Administration experience and a
74. Mahoney, E. M., Donfield, S. M., Howard, C., Kaufman, F.
review of the literature. Arch. Intern. Med. 15 (1997), 1651–6.
&Gerner, J. M. HIV-associated immune dysfunction and
57. Stockheim, J., Daaboul, J., Scully, S., Yogev, R. Scully, S. P., delayed pubertal development in a cohort of young hemophil-
Binns, H. J. & Chadwick, E. Adrenal suppression in HIV- iacs. Hemophilia Growth and Development Study. J. AIDS 21
infected children treated with megestrol acetate. J. Pediatr. (1999), 333–7.
134(3) (1999), 368–70.
75. Arnalich, F., Martinez, P., Hernanz, A. et al. Altered concentra-
58. Chantry, C., Gonz? alez de Pijem, L., Febo, I. & Lugo, L. tions of appetiteregulatorsmaycontributeto thedevelopment
Adrenal suppression secondary to megestrol acetate in HIV- and maintenance of HIV-associated wasting. AIDS 11 (1997),
infected children. 12th Int. Conf. AIDS (July 1998), 610 1129–34.
76. de Martino, M., Galli, L., Chiarelli, F. et al.Interleukin-6
59. Brady, M. T., Korany, K. I. &Hunkler, J. A. Megestrol acetate release by cultured peripheral blood mononuclear cells
for the treatment of anorexia associated with human immuno- inversely correlates with height velocity, bone age, insulin-like
deficiency virus infection in children. Pediatr. Inf. Dis. J. 13 growth. factor-I, and insulin-like growth factor binding protein-
(1994), 754–6. 3 serum levels in children with perinatal HIV-1 infection. Clin.
60. Briefel, R. R. & Woteki, C. E. Development of Food Immunol. 94 (2000), 212–18.
Sufficiency Questions for the Third National Health and 77. Mynarcik, D. C., Frost, R. A., Lang,C.H.et al.Insulin-like
Nutrition Exam-ination Survey. J. Nutr. Educ. 24 (1992), 24S– growth factor system in patients with HIV infection: effect of
8S. exogenous growth hormone administration. J. AIDS 22 (1999),
61. Henderson, R. A., Saavedra, J. M., Perman, J. A., Hutton, N., 49–55.
Livingston, R. A. & Yolken, R. H. Effect of enteral tube 78. Chantry, C., Cervia, J., Hughes, M., Patra, K., Hodge, J., Moye,
feeding on growth of children with symptomatic human J. and the PACTG Protocol 1010 Team. Body composition and
immunodeficiency virus infection. J. Pediatr. Gastroenterol. biochemical changes in children starting or switching com-
Nutr. 18 (1994), 429–34.
Руководство по оказанию помощи ВИЧ-инфицированным детям. Под ред. С. Зайхнера и Дж. Рид
24 Кэролайн Дж. Чентри, Джек Мойе-мл.
bination antiretroviral therapy. 10 th Conf. Retroviruses Oppor- 94. Moyle, G. J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia,
tunistic Infect. 2003 [Abstract No. 775]. S. & Gazzord, B. G. Dietary advice with or without pravastatin
for themanagementof hypercholesterolaemiaassociatedwith
79. Pinto, G., Blanche, S., Thiriet, I., Souberbielle, J. C., Goulet,
protease inhibitor therapy. AIDS 15 (2001), 1503–8.
O.&Brauner, R. Growth hormone treatment of children with
95. Jones, S. P., Doran, D. A., Leatt, P. B., Maher, B. & Pirmohamed,
human immunodeficiency virusassociated growth failure.
M. Shortterm exercise training improves body composition and
Eur. J. Pediatr. 159 (2000), 937–8.
hyperlipidaemia in HIV-positive individuals with lipodystrophy.
80. Fox-Wheeler, S., Heller, L., Salata, C. M. et al.Evaluation of [letter] AIDS 15 (2001), 2049–51.
the effects of oxandrolone on malnourished HIV-positive
96. Arpadi, S. M., Horlick, M., Thornton, J., Cuff, P. A., Wang, J.
pediatric patients. Pediatrics 104 (1999), e73.
&Kotler, D. P. Bone mineral content is lower in prepubertal HIV-
81. Lo, J. C., Mulligan, K., Noor, M. A. et al. The effects of infected children. J. AIDS 29 (2002), 450–4.
97. Mora, S., Sala, N., Bricalli, D. et al.Bone mineral loss through
human growth hormone on body composition and glucose increased bone turnover in HIV-infected children treated with
metabolism in HIV-infected patients with fat accumulation. highly active antiretroviral therapy. AIDS 15 (2001), 1823–9.
J. Clin. Endocrinol. Metab. 8 (2001), 3480–7.
98. Tebas, P., Powderly, W. G., Claxton, S. et al.Accelerated bone
82. Dreimane, D., Gallagher, K., Nielsen, K. et al.Growth hormone mineral loss in HIV-infected patients receiving potent antiretroviral
exerts potent anabolic effects in an adolescent with therapy. AIDS 14 (2000), F63–7.
human immunodeficiency virus wasting. Pediatr. Infect. Dis. 99. O’Brien, K. O., Razavi, M., Henderson, R. A., Caballero, B. &
J. 18 (1999), 167–9. Ellis, K. J. Bone mineral content in girls perinatally infected with
HIV. Am.J.Clin. Nutr. 73 (2001), 821–6.
83. Grinspoon, S., Corcoran, C., Stanley, T., Katznelson, L. &
Klibanski, A. Effects of androgen administration on the 100. Aukrust, P., Haug, C. J., Ueland, T. et al.Decreased bone formative
growth hormoneinsulin-like growth factor I axis in men and enhanced resorptive markers in human immunodeficiency virus
with acquired immunodeficiency syndrome wasting. J. Clin. infection: indication of normalization of the boneremodeling
Endocrinol. Metab. 83 (1998), 4251–6. process during highly active antiretroviral therapy. J. Clin.
Endocrinol. Metab. 84 (1999), 145–50.
84. Brambilla, P., Bricalli, D., Sala, N. et al.Highly active
101. Tan, B. M., Nelson, R. P., James-Yarish M, Emmanuel, P. J. &
antiretroviraltreated HIV-infected children showfat distribution
Schurman, S. J. Bone metabolism in children with human
changes even in absence of lipodystrophy. AIDS 15 (2001),
immunodeficiencyvirus infection receiving highly active anti-
retroviral therapy including a protease inhibitor. J. Pediatr. 139
85. Arpadi, S. M., Cuff, P. A., Horlick, M., Wang, J. & Kotler, (2001), 447–51.
D. R. Lipodystrophy in HIV-infected children is associated
102. Brown, P. & Crane, L. Avascular necrosis of bone in patients with
with high viral load and low CD4 +-lymphocyte count and
human immunodeficiency virus infection: report of 6 cases and
CD4 +-lymphocyte percentage at baseline and use of protease
review of the literature. Clin. Infect. Dis. 32 (2001), 1221–6.
inhibitors and stavudine. J. AIDS 27 (2001), 30–4.
103. Gaughan, D. M., Mofenson, L. M.&Hughes, M.D. Ostenecrosis of
86. Melvin, A. J., Lennon,S., Mohan,K. M.&Purnell, J. the hip (Legg–Calve–Perthes Disease) in human immuno-
Q.Metabolic deficiency virusinfected children. Pediatrics 109 (2002), e74.
abnormalities in HIV type 1-infected children treated and not
104. Sugerman, R. W., Church, J. A., Goldsmith, J. C. & Ens, G. E.
treated with protease inhibitors. AIDS Res. Hum. Retroviruses
Acquired protein S deficiency in children infected with. human
17 (2001), 1117–23. immunodeficiency virus. Pediatr. Infect. Dis. J. 15 (1996), 106–11.
87. Amaya, R. A., Kozinetz, C. A., McMeans, A., Schwarzwald, 105. Eldridge, J., Dilley, A., Austin, H. et al. The role of protein C,
H., & Kline, M. W. Lipodystrophy syndromein human protein S, and resistance to activated protein C in Legg-Perthes
immunodeficiency virusinfected children. Pediatr. Infect. Dis. disease. Pediatrics 107 (2001), 1329–34.
J. 21 (2002),
106. Cote, H. C., Brumme, Z. L., Craib, K. J. et al. Changes in
405–10. mitochondrial DNA as a marker of nucleoside toxicity in HIV-
88. Jaquet, D., Levine, M., Ortega-Rodriguez, E. et al. Clinical and infected patients. New Engl. J. Med. 346 (2002), 811–20.
metabolic presentation of the lipodystrophic syndrome in 107. Glesby, M.J. Overviewof mitochondrial toxicity of nucleoside
HIV-infected children. AIDS 14 (2000), 2123–8. reverse transcriptase inhibitors. Topics in HIV Med. 10 (2002),
89. Wanke, C., Gerrior, J., Kantaros, J., Coakley, E. & Albrecht,
M. Recombinant human growth hormone improves the fat 108. The Perinatal Safety Review Working Group. Nucleoside exposure
redistribution syndrome(lipodystrophy) in patients with HIV. in the children of HIV-infected women receiving antiretroviral
AIDS 13 (1999), 2099–103. drugs: absence of clear evidence for mitochondrial disease in
children who died before 5 years of age in five United States
90. Hadigan, C., Corcoran, C., Basgoz, N., Davis, B., Sax, P. &
cohorts. J. AIDS 25 (2000), 261–8.
Grinspoon, S. Metformin in the treatment of HIV lipodystrophy
109. Moyle, G. Clinical manifestations and management of antiretroviral
syndrome: a randomized controlled trial. J. Am. Med. Assoc.
nucleoside analogrelated mitochondrial toxicity. Clin. Ther. 22
284 (2000), 472–7.
91. Carr, A., Hudson, J., Chuah, J. et al. HIV protease inhibitor sub-
110. Falco, V., Rodriguez, D., Ribera, E. et al.Severe nucleoside-
stitution in patients with lipodystrophy: a randomized, con-
associated lactic acidosis in human immunodeficiency virusinfected
trolled, openlabel, multicentre study. AIDS 15 (2001), 1811–22.
patients: report of 12 cases and review of the literature. Clin. Infect.
92. Hatano, H., Miller, K. D., Yoder, C. P. et al.Metabolic and Dis. 34 (2002), 838–46.
anthropometric consequences of interruption of highly active 111. McComsey, G. A. &Lederman, M. M. High doses of riboflavin and
antiretroviral therapy. AIDS 14 (2000), 1935–42. thiamine may help in secondary prevention of hyperlactatemia.
AIDS Reader 12 (2002), 222–4.
93. Dube, M. P., Sprecher, D., Henry, W. K. et al.Preliminary
guidelines for the evaluation and management of dyslipidemia 112. Arrigoni-Martelli, E. & Caso, V. Carnitine protects mitochondria
in adults infected with human immunodeficiency virus and and removes toxic acyls from xenobiotics. Drugs Exp. Clin. Res. 27
receiving antiretroviral therapy: recommendations of the Adult (2001), 27–49.
AIDS Clinical Trial Group Cardiovascular Disease Focus 113. Fawzi, W. W., Mbise, R. L., Hertzmark, E. et al.Arandomized
Group. Clin. Infect. Dis. 31 (2000), 1216–24. trial of vitamin A supplements in relation to mortality among
Руководство по оказанию помощи ВИЧ-инфицированным детям. Под ред. С. Зайхнера и Дж. Рид
Питание, рост и метаболизм
human immunodeficiency virusinfected and uninfected children outcomes and T cell counts in HIV-1 infected women in
in Tanzania. Pediatr. Infect. Dis. J. 18 (1999), 127–33. Tanzania. Lancet 351 (1998), 1477–82.
114. Filteau, S. M., Rollins, N. C., Coutsoudis, A., Sullivan, K. R., 116. Amadi, B., Kelly, P., Mwiya, M. et al.Intestinal and systemic
Willumsen, J. F. & Tomkins, A. N. The effect of antenatal vita- infection, HIV, and mortality in Zambian children with per-
min A and betacarotene supplementation on gut integrity of sistent diarrhea and malnutrition. J. Pediatr. Gastroenterol.
infants of HIV-infected South African women. J. Pediatr. Nutr. 32 (2001), 550–4.